Jump to navigation
The Pharmacy and Therapeutics (P&T) Committee is an advisory board established pursuant to Executive Order D004-07. The committee performs clinical reviews of drug classes and makes recommendations which help the Department develop and manage the Medicaid Preferred Drug List (PDL).
The P&T Committee is required to consider clinical criteria such as drug safety and efficacy when making its recommendations. The committee also considers public comments and testimony related to the drug classes being reviewed or other PDL-related agenda items.
Our meeting has a standing location: 303 E. 17th Ave, 11th Floor Conference Room, Denver, Colorado 80203
1:00 p.m. - 5:00 p.m.
The Board meets once quarterly in January, April, July, and October
The P&T Committee consists of 7 physicians, 4 pharmacists and 2 client representatives, who are appointed by the Department's Executive Director. Review the Policies and Procedures Manual for more information on the committee's membership, duties and policies.
January 2017 - December 2018 Term
Michelle Hilaire, PharmD
Andrew Davis, PharmD
Scott Humphreys, MD
James Feinstein, MD
Steven Russell, MD
Kimberley Jackson, DO (Vice-Chairperson)
David Elwell, MD
January 2016 - December 2017 Term
Lynn Parry, MD (Chairperson)
Patricia M. Lanius, RPh
Roy Durbin, MD
Gwen Black, PharmD
Jennifer S. Hyer, MD
Reasonable accommodations for the meetings will be provided upon request for persons with disabilities. Please contact the Program Administrator at least one week prior to the scheduled meeting if you need special arrangements.
